Characteristics of the baseline biomarker-evaluable populations were almost entirely representative of the intent-to-treat population [18]; tumor grade, progesterone receptor (PgR) status, estrogen receptor (ER) status, tumor dimension (pT), axillary lymph node status (pN), and menopausal status were similar between populations (aside from slightly lower prevalence of ER-negative receptor status in the PIK3CA-evaluable population). The gene discussed is ESR1; the disease is neoplasm.